Head of dementia research at Austin Health.
Refining Alzheimer Treatment Through Biomarker-Based Patient Selection: Michael Woodward, MD, FRACP; Anthony Caggiano, MD, PhD
The head of dementia research at Austin Health and the chief medical officer at Cognition Therapeutics talked about recently presented phase 2 findings on CT1812, an investigational medicine for patients with mild to moderate Alzheimer disease, at CTAD 2024. [WATCH TIME: 5 minutes]